Paradigm Biopharmaceuticals (PAR) Fundamentals 2026 — Revenue Analysis | SniperIQ
Paradigm Biopharmaceuticals (PAR) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A$76M, trading at A$0.17 on the ASX. This SniperIQ fundamentals page covers Paradigm Biopharmaceuticals's valuation, profitability (net margin -59585.7%), revenue (A$52,120 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Paradigm Biopharmaceuticals's market cap?
Paradigm Biopharmaceuticals (PAR) has a market capitalization of approximately A$76M, trading at A$0.17 on the ASX. Market cap moves with the live share price.
What is Paradigm Biopharmaceuticals's P/E ratio?
Paradigm Biopharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 12.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Paradigm Biopharmaceuticals?
Paradigm Biopharmaceuticals runs a net profit margin of -59585.7%, a gross margin of -161.1%, and an operating margin of -63782.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Paradigm Biopharmaceuticals generate?
Paradigm Biopharmaceuticals reported revenue of A$52,120 for fiscal year 2025, with net income of -A
Does Paradigm Biopharmaceuticals pay a dividend?
Paradigm Biopharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Paradigm Biopharmaceuticals financially healthy?
Paradigm Biopharmaceuticals carries a debt-to-equity ratio of 0.17x and a current ratio of 1.31x, with a market beta of -0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Paradigm Biopharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Paradigm Biopharmaceuticals (PAR) the key facts are: market cap A$76M, revenue A$52,120, 52-week range 0.135-0.47. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Paradigm Biopharmaceuticals's full fundamentals live
Get Paradigm Biopharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.